| PROTAC targeted protein degraders: the past is prologue | 2022/01/18 | English | 880 |
| Epigenetic therapy of cancer: past, present and future | 2006/01/01 | English | 875 |
| Induced protein degradation: an emerging drug discovery paradigm | 2016/11/25 | English | 874 |
| Interfering with disease: a progress report on siRNA-based therapeutics | 2007/06/01 | English | 856 |
| Induced pluripotent stem cell technology: a decade of progress | 2016/12/16 | English | 849 |
| Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases | 2013/05/31 | English | 844 |
| Emerging applications of metabolomics in drug discovery and precision medicine | 2016/03/11 | English | 842 |
| Adenosine receptors: therapeutic aspects for inflammatory and immune diseases | 2008/09/01 | English | 836 |
| Interferons at age 50: past, current and future impact on biomedicine | 2007/12/01 | English | 820 |
| Inhaling medicines: delivering drugs to the body through the lungs | 2007/01/01 | English | 818 |
| RNA therapeutics: beyond RNA interference and antisense oligonucleotides | 2012/01/20 | English | 814 |
| Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework | 2014/05/16 | English | 811 |
| The current state and future directions of RNAi-based therapeutics | 2019/03/07 | English | 807 |
| The ascent of mouse: advances in modelling human depression and anxiety | 2005/09/01 | English | 803 |
| An analysis of the attrition of drug candidates from four major pharmaceutical companies | 2015/06/19 | English | 802 |
| Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia | 2004/04/01 | English | 793 |
| Is NF-κB a good target for cancer therapy? Hopes and pitfalls | 2009/01/01 | English | 793 |
| Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy | 2012/02/01 | English | 791 |
| Alzheimer's disease: strategies for disease modification | 2010/05/01 | English | 790 |
| Organs-on-chips at the frontiers of drug discovery | 2015/03/20 | English | 789 |
| Principles for modulation of the nuclear receptor superfamily | 2004/11/01 | English | 787 |
| Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism | 2003/08/01 | English | 779 |
| Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases | 2019/01/04 | English | 778 |
| Protein drug stability: a formulation challenge | 2005/04/01 | English | 774 |
| Trends in peptide drug discovery | 2021/02/03 | English | 768 |
| Molecular imaging in drug development | 2008/07/01 | English | 764 |
| Targeting RAS–ERK signalling in cancer: promises and challenges | 2014/12/01 | English | 763 |
| Potential therapeutic applications of autophagy | 2007/04/01 | English | 761 |
| Impact of high-throughput screening in biomedical research | 2011/03/01 | English | 759 |
| Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders | 2009/01/01 | English | 758 |